ストックスクリーナーアプリを入手
104.67
0.12%
0.13
アフターアワーズ：
106.20
1.53
+1.46%
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Braun Stacey Associates Inc. Acquires 4,827 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Thrivent Financial for Lutherans Has $78.04 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Aigen Investment Management LP - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Mizuho Markets Americas LLC - MarketBeat
Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now - Insider Monkey
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Simplify Asset Management Inc. - MarketBeat
12 High Growth Large Cap Stocks to Buy Now - Insider Monkey
Relative Strength Alert For Sarepta Therapeutics - Nasdaq
Janus Henderson Group PLC's Strategic Acquisition in Sarepta The - GuruFocus.com
Capital International Investors Expands Stake in Sarepta Therape - GuruFocus.com
Sarepta Therapeutics' SWOT analysis: stock poised for growth amid DMD market leadership - Investing.com
Gene Therapy For Rare Disease Market Growth Demand, Segment - openPR
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News - Simply Wall St
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem - Yahoo Finance
Sarepta stops development of exon 51-skipping therapy for DMD - Muscular Dystrophy News
Sarepta recent weakness brings buying opportunity, says JPMorgan - Yahoo Finance
Assetmark Inc. Acquires 27,220 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Principal Financial Group Inc. Decreases Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Sarepta halts development of Duchenne drug as Elevidys soars - The Pharma Letter
Oligonucleotide Therapy Market to Witness Huge Growth by 2031: - openPR
Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Reduced by Fiera Capital Corp - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2024 Earnings Call Transcript - Insider Monkey
Sarepta price target lowered to $193 from $200 at Baird - Yahoo Finance
Sarepta’s Elevidys Sales Surge, But Next-Gen DMD Drug Platform Discontinued - Citeline News & Insights
Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales - FiercePharma
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 7.6% After Analyst Downgrade - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $150.00 - MarketBeat
Robert W. Baird Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $193.00 - MarketBeat
Sarepta sees strong sales on approved Duchenne treatment, stops work on clinical-stage drug - The Business Journals
Sarepta upgraded at Cantor on pipeline, growth potential - Seeking Alpha
Sarepta scraps a Duchenne drug as gene therapy sales rise - BioPharma Dive
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $170.00 by Analysts at Evercore ISI - MarketBeat
Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales - BioSpace
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program - Yahoo Finance
Sarepta Therapeutics' (SRPT) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Van ECK Associates Corp Has $8.85 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript - Barchart
Sarepta pulls plug on Duchenne exon-skipping drug - pharmaphorum
Sarepta reports strong 3rd-qtr 2024 sales growth - The Pharma Letter
Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges - GuruFocus.com
Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments - BioSpace
Sarepta Therapeutics: Q3 Earnings Snapshot - Barchart
Sarepta Therapeutics Shows Financial Growth in 2024 - TipRanks
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market EvolutionTechnavio - cnhinews.com
Sarepta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
AlphaCentric Advisors LLC Has $2.25 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Emerald Advisers LLC Buys 4,059 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Gladstone Institutional Advisory LLC Acquires 26,900 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Interesting SRPT Put And Call Options For December 13th - Nasdaq
Pinnacle Associates Ltd. Has $11.48 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (SRPT) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by abrdn plc - MarketBeat
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):